ABSTRACT 5-Lipoxygenase (5-LO; EC 1.13.11.34) activity in the human monocytic cell line Mono Mac 6 was upregulated by combined treatment with transforming growth factor .31 Leukotrienes are produced by granulocytes, mast cells, monocytes, and macrophages after stimulation, and the capacity for leukotriene biosynthesis of these cells is supposedly acquired during cell maturation. Arachidonate 5-lipoxygenase (5-LO; EC 1.13.11.34) is a key enzyme, which catalyzes two initial steps in leukotriene biosynthesis (1), and 5-LO mRNA, protein expression, and activity were shown to be upregulated after in vitro differentiation of the human promyeloic cell line HL-60 (2-5). Human monocytes and macrophages express 5-LO mRNA and protein (6, 7), and differentiation of monocytes to macrophages is accompanied by an upregulation of 5-LO activity and protein expression (8-10).
Transforming growth factor ,B (TGF-13) was recently found to upregulate cellular 5-LO activity in dimethyl sulfoxide (DMSO)-differentiated HL-60 cells (11) . The most prominent effects of TGF-,B were observed for the 5-LO activity of intact cells, whereas the amount of 5-LO protein was less affected. It was concluded that TGF-f3 induced or modified other components of importance for 5-LO activity in the intact cell.
To identify factors that induce 5-LO activity during monocytic differentiation, we studied the effects of TGF-f3 and other differentiation inducers on the human monocytic cell line Mono Mac 6, which has characteristics of mature monocytes (12) . Under standard cell culture conditions, Mono Mac 6 cells do not express detectable amounts of 5-LO protein or activity
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MATERIALS AND METHODS Materials. HPLC solvents and DMSO were from Merck, and molecular biology reagents were from Sigma, GIBCO, or Promega. Fetal calf serum and human transferrin were obtained from Sigma; RPMI 1640 medium was from GIBCO. Insulin was a gift from Hoechst-Roussel. 5-LO antiserum was kindly provided by Armin Hatzelmann, Bayer (Leverkusen, F.R.G.). PCR primers were purchased from Scandinavian Gene Synthesis (Koping, Sweden) or Roth (Karlsruhe, F.R.G.). Human TGF-f31 was purified from outdated platelets as described (13), except that the Bio-Sil TSK CM-2-SW column (Bio-Rad) was replaced by a LiChrospher 1000 COOcolumn (10 x 100 mm) (Merck). VD3 was kindly provided by Ulf Fischer (Hoffmann-La Roche).
Cells. Mono Mac 6 cells were kindly provided by H. W. L. Ziegler-Heitbrock (Munich) and maintained in RPMI 1640 supplemented with 10% (vol/vol) fetal calf serum, streptomycin at 100 jig/ml, penicillin at 100 units/ml, 1 mM sodium pyruvate, 1 X nonessential amino acids, 1 mM oxalacetic acid, and bovine insulin at 10 ,g/ml (12) . Cultures were seeded at a density of 2 x 105 cells per ml.
Determination of 5-LO Activity. Cells were harvested after the indicated times and washed once in phosphate-buffered saline (PBS). When intact cells were assayed, the cells (2-10 x 106) were finally taken up in 1 ml of PBS (with 1 mM Ca2+ and glucose at 1 g/liter), and the reaction was started by addition of arachidonic acid and ionophore A23187 in 10 ,ul of methanol (40 ,tM and 10 ,uM final concentrations, respectively).
After 10 min at 37°C, the reaction was stopped with 1 ml of methanol and 30 ,ul of 1 M HCI; 200 ng of prostaglandin B1 (internal standard) and 500 ,ul of PBS were added. The samples were centrifuged (800 x g, 10 min), and the supernatant was applied to C18 solid-phase extraction columns (100 mg, preconditioned with 1 ml of methanol and 1 ml of water). After washing with 1 ml of water and 1 ml of 25% (vol/vol) methanol, 5-LO metabolites were eluted with 300 ,ul of methanol. The eluate was diluted with 120 ,ul of water, and 100 ,ul of the diluted extract was analyzed by HPLC as described (14) .
When cell homogenates were assayed, the cells were finally taken up in 1 ml of PBS (with glucose at 1 g/liter and without Ca2+ and Mg2+) and cooled on ice. After addition of EDTA (1 mM), sonication (three times for 5 sec each), and addition of 1 mM ATP, the samples were preincubated for 30 sec at Abbreviations: TGF-f3, transforming growth factor 13; 5 (Fig. 1A) . The combination of TGF-,3 and VD3 strongly induced 5-LO activity in intact cells and cell homogenates (791 ± 7 and 524 ± 70 ng per 106 cells, respectively; n = 3). The detection limit of the HPLC assay was 1 ng per 106 cells, and in samples from undifferentiated cells 5-LO activity was undetectable; thus, the activity was upregulated at least 500-fold. This prominent upregulation (1 ng/ml) ( (Fig. 2, lane 1) . Clear bands were observed in samples from cells that received TGF-3, VD3, or DMSO (lanes 2-4) . The combination of TGF-, with VD3 led to the strongest induction of 5-LO mRNA (lane 5). Treatment of cells with TGF-13 and DMSO gave a slightly stronger signal (lane 6) as compared to TGF-f3 or DMSO alone.
The differences in 5-LO mRNA expression were determined with competitive PCR (Fig. 3) . The (Fig. 4A) . 5 (Fig. 4 B and C) . Without preincubation, full upregulation of 5-LO activity required 3 days (Fig. 4A) . Thus (Fig. 4) (lanes 1 and 2), 12 h (lanes 3 and 4) , 4 days), granulocytes, or lymphocytes gave 11.8 ± 2.5 (n = 3), 9.2 ± 3.3 (n = 2), and 9.0 ± 1.2 ng (n = 4) of products, respectively.
Effect of Cycloheximide on 5-LO mRNA Induction. To check whether protein synthesis is required for induction of 5-LO mRNA, cells receiving TGF-P3 (1 ng/ml) and VD3 (50 nM) were cultured in the presence or absence of 10 tM .* cycloheximide (Fig. 5) . After Proc. NatL Acad ScL USA 92 (1995) protein expression but also apparently leads to either a modification of the 5-LO protein that increases its specific activity or induces or modifies other cellular components of importance for 5-LO activity. Differences between activity and protein expression were also observed when time courses of induction of 5-LO activity and protein expression were investigated (Fig. 4) . In comparison to the upregulation of 5-LO protein expression, appearance of activity was delayed. Moreover, pretreatment of cells with TGF-f3 or VD3 alone for 2 days induced 5-LO protein but almost no activity; addition of the second inducer was required for upregulation of the activity (Fig. 4 B and C) .
To clarify whether the observed differencies in activity were due to modifications of the 5-LO protein or to other cellular components, 5-LO was partially purified from cells with low activity (grown with TGF-f3 for 2 days) by ATP-agarose column chromatography. This preparation of 5-LO was then recombined with ATP-PT fractions containing most of the soluble cellular proteins, and 5-LO activities were determined. 5-LO activity was inhibited when this enzyme preparation was recombined with the original ATP-PT fraction. On the other hand, recombination with ATP-PT fractions prepared from Mono Mac 6 cells treated with TGF-f3 plus VD3, granulocytes, or the B-lymphocytic cell line BL41E95A resulted in increased enzyme activity. Apparently, 5-LO in Mono Mac 6 cells grown for 2 days in the presence of TGF-, is inhibited by cytosolic components. In addition, these cells could lack an activator that may be present in ATP-PT fractions from Mono Mac cells grown for 4 days in the presence of TGF-,B and VD3, granulocytes, or lymphocytes.
Synergistic effects of TGF-f3 and VD3 on leukemic cell lines have been described (19, 20) . A number of differentiationrelated parameters were affected, and it was concluded that TGF-f3 plus VD3 together stimulate the terminal differentiation of monocytic cells. It appears reasonable that the effects on 5-LO are part of such a differentiation process. Synergistic effects of these agents have also been seen for other cell types. One interesting example was the 40-to 70-fold upregulation of alkaline phosphatase activity in MG-63 osteosarcoma cells, combined with 5-to 6-fold upregulation of mRNA and protein (21) . We previously found an upregulatory effect of TGF-13, primarily on 5-LO activity, in DMSO-differentiated HL-60 cells (11) . In those studies, the presence of a cellular lipid fraction was required to have the best effect of TGF-j. It is conceivable that this lipid fraction contained VD3.
The mechanism for stimulation of expression of 5-LO by TGF-,B plus VD3 in Mono Mac 6 cells should involve upregulation of transcription or effects on mRNA stability. Both alternatives are compatible with the effect of cycloheximide on 5-LO mRNA (Fig. 5) , which indicated that protein biosynthesis (transcription factors or mRNA stabilizing proteins) was required for the increased expression.
